1.
Nat Rev Drug Discov
; 15(9): 589-590, 2016 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27469032
RESUMO
A global response to the chronic shortfall in antibiotic innovation is urgently needed to combat antimicrobial resistance. Here, we introduce CARB-X, a new global public-private partnership that will invest more than US$350 million in the next 5 years to accelerate the progression of a diverse portfolio of innovative antibacterial products into clinical trials.